It is noteworthy that, in three cohorts of breast cancer patients, the expression of GLS2 was significantly higher in tumors than in normal tissues; analysis of publicly available datasets (TCGA and the International Cancer Genome Consortium) revealed a correlation between high GLS2 expression and decreased overall, disease-free, and distant metastasis-free survival [79]. Here, GLS2 is linked to breast cancer.